Unique features of trabectedin mechanism of action

[1]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Mora,et al.  The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin , 2015, Oncotarget.

[3]  B. Monk,et al.  Patients and Methods: a Candidate Array Was Designed Based on the Breast Cancer Information Core Database For , 2022 .

[4]  C M Galmarini,et al.  Mode of action of trabectedin in myxoid liposarcomas , 2014, Oncogene.

[5]  J. Lubiński,et al.  Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. D’Incalci,et al.  Resistance to minor groove binders. , 2014, Drug discovery today. Technologies.

[7]  S. Burdach.  Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies? , 2014, Clinical Cancer Research.

[8]  P. Allavena,et al.  Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment , 2014, Marine drugs.

[9]  Y. Pommier,et al.  Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth , 2013, Clinical Cancer Research.

[10]  F. Gago,et al.  Inhibitory effects of marine‐derived DNA‐binding anti‐tumour tetrahydroisoquinolines on the Fanconi anaemia pathway , 2013, British journal of pharmacology.

[11]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[12]  B. Schäfer,et al.  Small‐molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma , 2012, International journal of cancer.

[13]  J. Blay,et al.  A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. , 2012, European journal of cancer.

[14]  A. Escargueil,et al.  The DNA damage response to monofunctional anticancer DNA binders , 2012 .

[15]  J. Blay,et al.  Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Cordon-Cardo,et al.  PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. , 2012, The Journal of clinical investigation.

[17]  Juan A. Bueren-Calabuig,et al.  XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids. , 2011, Chemistry & biology.

[18]  Juan A. Bueren-Calabuig,et al.  Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations , 2011, Nucleic acids research.

[19]  J. Dahm-Daphi,et al.  FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. , 2011, Cancer letters.

[20]  A. Escargueil,et al.  Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells , 2011, Molecular Cancer Therapeutics.

[21]  J. Blay,et al.  Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. , 2011, European journal of cancer.

[22]  J. Khan,et al.  Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. , 2011, Neoplasia.

[23]  F. Grosso,et al.  Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors , 2010, Clinical Cancer Research.

[24]  C. Galmarini,et al.  A Review of Trabectedin (ET-743): A Unique Mechanism of Action , 2010, Molecular Cancer Therapeutics.

[25]  S. Patrick,et al.  Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. , 2010, DNA repair.

[26]  B. Monk,et al.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Allavena,et al.  Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. , 2010, Cancer research.

[28]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Zucchetti,et al.  Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. , 2009, European journal of cancer.

[30]  Andrés Francesch,et al.  Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. , 2009, Natural product reports.

[31]  F. Grosso,et al.  Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors , 2009, Molecular Cancer Therapeutics.

[32]  Y. Pommier,et al.  Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to Trabectedin , 2008, Clinical Cancer Research.

[33]  Y. Pommier,et al.  Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. , 2008, Molecular biology of the cell.

[34]  J. Vaquero,et al.  Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin , 2008, Molecular Cancer Therapeutics.

[35]  M. D’Incalci,et al.  Role of homologous recombination in trabectedin-induced DNA damage. , 2008, European journal of cancer.

[36]  S. Lessnick,et al.  A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature , 2008, Cell cycle.

[37]  C. Natoli,et al.  Dynamics of cell cycle phase perturbations by trabectedin (ET‐743) in nucleotide excision repair (NER)‐deficient and NER‐proficient cells, unravelled by a novel mathematical simulation approach , 2007, Cell proliferation.

[38]  A. Escargueil,et al.  Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 , 2007, Proceedings of the National Academy of Sciences.

[39]  J. Soria,et al.  Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma , 2007, Clinical Cancer Research.

[40]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[41]  J. Svejstrup.  Contending with transcriptional arrest during RNAPII transcript elongation. , 2007, Trends in biochemical sciences.

[42]  C. Bailly,et al.  Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. , 2006, Journal of medicinal chemistry.

[43]  S. Moreno,et al.  Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. , 2006, Cancer research.

[44]  R. Mantovani,et al.  Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters , 2005, Molecular Pharmacology.

[45]  D. Bonatto,et al.  Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. , 2005, Biochemical pharmacology.

[46]  P. Allavena,et al.  Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. , 2005, Cancer research.

[47]  F. D. De Braud,et al.  Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Sandberg.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. , 2004, Cancer genetics and cytogenetics.

[49]  S. Broyde,et al.  Human RNA polymerase II is partially blocked by DNA adducts derived from tumorigenic benzo[c]phenanthrene diol epoxides: relating biological consequences to conformational preferences. , 2003, Nucleic acids research.

[50]  C. Sessa,et al.  The combination of yondelis and cisplatin is synergistic against human tumor xenografts. , 2003, European journal of cancer.

[51]  E. Raymond,et al.  Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  J. Egly,et al.  Transcriptional activators stimulate DNA repair. , 2002, Molecular cell.

[53]  K. Scotto,et al.  Ecteinascidin-743 inhibits activated but not constitutive transcription. , 2002, Cancer research.

[54]  K. Scotto,et al.  ET‐743: More than an innovative mechanism of action , 2002, Anti-cancer drugs.

[55]  Y. Pommier,et al.  Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair , 2001, Nature Medicine.

[56]  P. McHugh,et al.  Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. , 2001, The Lancet. Oncology.

[57]  M. D’Incalci,et al.  Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways , 2001, International journal of cancer.

[58]  E. Raymond,et al.  Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Mosesso,et al.  Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage. , 2000, Mutation research.

[60]  P. McHugh,et al.  Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian Cells , 2000, Molecular and Cellular Biology.

[61]  R. Mantovani,et al.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Jin,et al.  Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  L. Hurley,et al.  Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. , 1999, Journal of medicinal chemistry.

[64]  R. Mantovani,et al.  Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. , 1999, Anti-cancer drug design.

[65]  P. Leder,et al.  A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[66]  E. Raymond,et al.  In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  M. D’Incalci,et al.  Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  K. Kohn,et al.  DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. , 1996, Biochemistry.

[69]  Paul A. Keifer,et al.  Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata , 1990 .

[70]  B. Monk,et al.  Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. , 2014, Gynecologic oncology.

[71]  M D'Incalci,et al.  Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. , 2001, European journal of cancer.